Important Notice: Our web hosting provider recently started charging us for additional visits, which was unexpected. In response, we're seeking donations. Depending on the situation, we may explore different monetization options for our Community and Expert Contributors. It's crucial to provide more returns for their expertise and offer more Expert Validated Answers or AI Validated Answers. Learn more about our hosting issue here.

What is the rationale for testing this treatment in patients with B-cell chronic lymphocytic leukemia (CLL)?

April 26, 2017B-cell chronic cll leukemia lymphocytic Patients rationale Testing treatment

0

Posted

What is the rationale for testing this treatment in patients with B-cell chronic lymphocytic leukemia (CLL)?

1 Answer

0

Posted

Idiotype vaccines were first studied in clinical trials conducted by Stanford University Medical Center and the National Cancer Institute. Genitope Corporation’s lead product candidate, MyVax® Personalized Immunotherapy, has been studied in phase 2 trials in patients with B-cell non-Hodgkin’s lymphoma (NHL) and is currently being evaluated in a phase 3 study in patients with follicular lymphoma. Encouraging efficacy results and a favorable safety profile have been seen to date in these studies. Since CLL is another type of B-cell–related malignancy, it is thought that MyVax® Personalized Immunotherapy may be helpful in this patient population.